Anorgasmia has many causes, it is believed that approximately 90% of anorgasmia problems are related to psychological issues, and some cases may result from the use of certain drugs such as serotoninergic
drugs including antidepressants (particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors), antiepileptic, and antipsychotic drugs (3,4).
mechanisms in the treatment of obsessive-compulsive disorder.
(5HT2A) and adrenergic ([[alpha].
25) Adrenocorticotropic hormone, opiate, (26) dopaminergic, and serotoninergic
systems (27) have been shown to influence the onset, development, and maintenance of feather-damaging behavior.
In addition, a new serotonin-based DOTA conjugate offers the potential to image serotoninergic
neurotransmission using a radioisotope or with gadolinium by magnetic resonance imaging (MRI).
Arango, "The Neurobiology and Genetics of Suicide and Attempted Suicide: A Focus on the Serotoninergic
System," Neuropsychopharmacology 24 (2001): 467-77.
, peptidergic and GABAergic innervation of the ventrolateral and dorsolateral motor nuclei in the cat S1/S2 segments: an immunofluorescence study.
The combination of MAO inhibitors such as some ayahuasca j carbolines with monoaminergic and serotoninergic
substances in general, antidepressives, as well as ginseng, St John's wort, dextromethorphan, amphetamine, and 3,4-methylenedioxymethamphetamine (MDMA: "ecstasy"), could produce the serotonin syndrome (dos Santos 2013a; Pilgrim et al.
The cause of depression in PD is complex involving biochemical disturbances mainly of the serotoninergic
or dopaminergic system (Cummings, 1992; Mayeux et al.
Thus the diencephalic endorphin and mesencephalic enkephalin neurons stimulate the serotonin neurons at the bulbus (28-30) The serotoninergic
neurons at the dorsal horn of the spinal cord stimulate the intermediate neurons at the dorsal horn.
20) Preliminary data from neurochemical studies of FTD patients, as well as functional PET imaging using serotonin receptors, have indicated abnormalities in serotonin metabolism, which has led to clinical trials of drugs with serotoninergic
A number of physiological differences are reported in persons with PTSD, including disturbances in neurological integration of the fear circuitry , reduced serotoninergic
modulation of the fear response in key areas such as the amygdala , and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis.